Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision - London, CA; Malpas, PB; Wood-Follis, SL; Boucher, JF; Rusk, AW; Rosenberg, MP; Henry, CJ; Mitchener, KL; Klein, MK; Hintermeister, JG; Bergman, PJ; Couto, GC; Mauldin, GN; Michels, GM (Clin Cancer Res, 2009)